Ciforadenant

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameCiforadenant
Drug Alias NameAdenosine A2A Receptor Antagonist - CorvusImmune checkpoint inhibitor ACPI-444V-81444
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdenosine A2a receptor antagonists
TargetsAdenosine A2a receptor
Therapy Area/IndicationsAttention Deficit Disorder with HyperactivityParkinson DiseaseCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesVernalis (R&D) Ltd
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer CenterCorvus Pharmaceuticals Inc +[3] 
Inactive CompaniesF. Hoffmann-La Roche AgVernalis (R&D) Ltd
Active IndicationsMultiple MyelomaCarcinoma, Renal CellNeoplasms
Inactive IndicationsAttention Deficit Disorder with HyperactivityParkinson DiseaseCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A